Thaum Lub Yim Hli 2020, ib lub tuam txhab Canadian biotech pharma "FSD Pharma" tau txais lub teeb ntsuab los ntawm Food and Drug Administration los tsim cov ntaub ntawv pov thawj-ntawm-tsim kev tshawb fawb soj ntsuam cov teebmeem ntawm ultra micronized palmitoylethanolamide bulk (PEA) hauv COVID-19 cov neeg mob.
FSD Pharma tau foob IND nrog FDA thaum Lub Yim Hli 28, 2020, thiab tau pom zoo rau lub Cuaj Hlis 25, 2020, txhawm rau pib qhov kev sim tshuaj thib 2 rau kev siv FSD201 los kho COVID-19, tus kab mob tshwm sim los ntawm SARS -CoV-2 virus.
Tam sim no, FSD Pharma tau ua tiav Phase 1 ua ntej-hauv-tib neeg kev nyab xeeb thiab zam kev sim uas tsis muaj qhov cuam tshuam loj heev nrhiav pom.
Tus thawj neeg sib tw yog FSD201-600mg ultra-micronized-PEA
Target indications rau theem 2a mus sib hais:
COVID-19
Lub hom phiaj muaj peev xwm qhia qhov chaw rau Phase 2 sim:
Osteoarthritis ntawm lub hauv caug
Cov poj niam kev noj qab haus huv, suav nrog endometriosis
Kev mob ntev, suav nrog kev hloov tshuaj opioid thiab / lossis sparing
Peb tuaj yeem pom cov hauv qab no los ntawm lub vev xaib ntawm FSD Pharma:
